Logo image of KRRO

KORRO BIO INC (KRRO) Stock Fundamental Analysis

NASDAQ:KRRO - Nasdaq - US5009461089 - Common Stock - Currency: USD

15.16  -0.45 (-2.88%)

Premarket: 15.6 +0.44 (+2.9%)

Fundamental Rating

3

Overall KRRO gets a fundamental rating of 3 out of 10. We evaluated KRRO against 553 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for KRRO as it has an excellent financial health rating, but there are worries on the profitability. KRRO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KRRO had negative earnings in the past year.
In the past year KRRO has reported a negative cash flow from operations.
In the past 5 years KRRO always reported negative net income.
In the past 5 years KRRO always reported negative operating cash flow.
KRRO Yearly Net Income VS EBIT VS OCF VS FCFKRRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -43.23%, KRRO is in line with its industry, outperforming 54.61% of the companies in the same industry.
KRRO's Return On Equity of -62.91% is in line compared to the rest of the industry. KRRO outperforms 58.95% of its industry peers.
Industry RankSector Rank
ROA -43.23%
ROE -62.91%
ROIC N/A
ROA(3y)-50.75%
ROA(5y)-35.9%
ROE(3y)-63.13%
ROE(5y)-44.24%
ROIC(3y)N/A
ROIC(5y)N/A
KRRO Yearly ROA, ROE, ROICKRRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KRRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KRRO Yearly Profit, Operating, Gross MarginsKRRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

7

2. Health

2.1 Basic Checks

KRRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
KRRO has more shares outstanding than it did 1 year ago.
KRRO has less shares outstanding than it did 5 years ago.
KRRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KRRO Yearly Shares OutstandingKRRO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
KRRO Yearly Total Debt VS Total AssetsKRRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -1.55, we must say that KRRO is in the distress zone and has some risk of bankruptcy.
KRRO has a Altman-Z score (-1.55) which is in line with its industry peers.
There is no outstanding debt for KRRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.55
ROIC/WACCN/A
WACC9.83%
KRRO Yearly LT Debt VS Equity VS FCFKRRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

KRRO has a Current Ratio of 9.41. This indicates that KRRO is financially healthy and has no problem in meeting its short term obligations.
KRRO has a better Current ratio (9.41) than 76.85% of its industry peers.
KRRO has a Quick Ratio of 9.41. This indicates that KRRO is financially healthy and has no problem in meeting its short term obligations.
KRRO's Quick ratio of 9.41 is fine compared to the rest of the industry. KRRO outperforms 77.03% of its industry peers.
Industry RankSector Rank
Current Ratio 9.41
Quick Ratio 9.41
KRRO Yearly Current Assets VS Current LiabilitesKRRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 83.89% over the past year.
KRRO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -39.89% yearly.
EPS 1Y (TTM)83.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.05%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-45.55%
Revenue growth 5Y-39.89%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 5.00% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.69%
EPS Next 2Y0.72%
EPS Next 3Y-1.02%
EPS Next 5Y5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KRRO Yearly Revenue VS EstimatesKRRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
KRRO Yearly EPS VS EstimatesKRRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KRRO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KRRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KRRO Price Earnings VS Forward Price EarningsKRRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KRRO Per share dataKRRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.72%
EPS Next 3Y-1.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KRRO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KORRO BIO INC

NASDAQ:KRRO (7/29/2025, 8:00:02 PM)

Premarket: 15.6 +0.44 (+2.9%)

15.16

-0.45 (-2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-19 2025-08-19/amc
Inst Owners104.06%
Inst Owner Change-0.26%
Ins Owners0.42%
Ins Owner Change0%
Market Cap142.35M
Analysts85
Price Target97.13 (540.7%)
Short Float %12.55%
Short Ratio7.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.44%
Min EPS beat(2)6.23%
Max EPS beat(2)10.66%
EPS beat(4)4
Avg EPS beat(4)8.13%
Min EPS beat(4)0.53%
Max EPS beat(4)15.11%
EPS beat(8)7
Avg EPS beat(8)-111.92%
EPS beat(12)10
Avg EPS beat(12)-73.61%
EPS beat(16)10
Avg EPS beat(16)-88.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-21.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.97%
EPS NY rev (1m)0%
EPS NY rev (3m)9.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)328.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.53
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-9.44
EYN/A
EPS(NY)-9.25
Fwd EYN/A
FCF(TTM)-7.99
FCFYN/A
OCF(TTM)-6.67
OCFYN/A
SpS0.51
BVpS14.8
TBVpS14.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.23%
ROE -62.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.75%
ROA(5y)-35.9%
ROE(3y)-63.13%
ROE(5y)-44.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 305.36%
Cap/Sales 257.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.41
Quick Ratio 9.41
Altman-Z -1.55
F-Score4
WACC9.83%
ROIC/WACCN/A
Cap/Depr(3y)307.52%
Cap/Depr(5y)347.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.05%
EPS Next Y-3.69%
EPS Next 2Y0.72%
EPS Next 3Y-1.02%
EPS Next 5Y5%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-45.55%
Revenue growth 5Y-39.89%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-36.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.82%
OCF growth 3YN/A
OCF growth 5YN/A